Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14819942 | 1.00 | CYP3A4 (0.37) | CYP3A4LMNARORCTP53SMN1; SMN2 | |
| SCHEMBL14805550 | 1.00 | CYP3A4 (0.37) | CYP3A4LMNARORCTP53SMN1; SMN2 | |
| SCHEMBL12848830 | 0.94 | CYP3A4 (0.39) | CYP3A4LMNATP53SMN1; SMN2 | |
| SCHEMBL17145964 | 0.94 | CYP3A4 (0.39) | CYP3A4LMNATP53SMN1; SMN2 | |
| SCHEMBL23277703 | 0.94 | CYP3A4 (0.39) | CYP3A4LMNATP53SMN1; SMN2 | |
| SCHEMBL24106455 | 0.94 | CYP3A4 (0.39) | CYP3A4LMNATP53SMN1; SMN2 | |
| SCHEMBL14819927 | 0.94 | CYP3A4 (0.39) | CYP3A4LMNATP53SMN1; SMN2 | |
| SCHEMBL13854432 | 0.92 | RORC (0.36) | CYP3A4LMNARORCTP53SMN1; SMN2 | |
| SCHEMBL14819868 | 0.92 | CYP3A4 (0.34) | CYP3A4LMNARORC | |
| SCHEMBL14805551 | 0.91 | CYP3A4 (0.33) | CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150608-B2 | Neuro-protective compounds and their use | Biotechnology Research Corp. Ltd. (CN) | 2015-10-06 | — | — | US | disclosed |
| US-20130079293-A1 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079293-A1 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS | GRIN2B, GRM7, GRM2 | CYP3A4 4471/4885LMNA 4301/4885RORC 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.